Role of the endocannabinoid system in brain functions relevant for schizophrenia: An overview of human challenge studies with cannabis or ∆9-tetrahydrocannabinol (THC)

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 52, Issue , 2014, Pages 53-69

  Bossong, Matthijs G ^a   Jansma, J Martijn ^b   Bhattacharyya, Sagnik ^a   Ramsey, Nick F ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cannabis; Cognition; Endocannabinoid system; Neuroimaging; Schizophrenia; increment 9 Tetrahydrocannabinol (THC)

Indexed keywords

CANNABIS; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DRONABINOL; CANNABINOID RECEPTOR AGONIST; DOPAMINE; ENDOCANNABINOID;

ANHEDONIA; AUDITORY PROCESSING; BRAIN FUNCTION; COGNITIVE DEFECT; CORPUS STRIATUM; DEFAULT MODE NETWORK; DISEASE ASSOCIATION; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; EMOTIONAL PROCESSING; ENDOCANNABINOID SYSTEM; EXECUTIVE FUNCTION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MEMORY; MEMORY ENCODING; NERVOUS SYSTEM; NEUROIMAGING; NEUROMODULATION; NEUROPATHOLOGY; NEUROPSYCHOLOGY; PREFRONTAL CORTEX; RECALL; RESPONSE INHIBITION; REVIEW; REWARD; SALIENCE PROCESSING; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TASK PERFORMANCE; TEMPORAL CORTEX; VISUAL PROCESSING; WORKING MEMORY; ANIMAL; BRAIN; CHEMICALLY INDUCED; COGNITION; DRUG EFFECTS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BRAIN; CANNABINOID RECEPTOR AGONISTS; COGNITION; DOPAMINE; DRONABINOL; ENDOCANNABINOIDS; HUMANS; NEUROIMAGING; SCHIZOPHRENIA;

EID: 84899638982     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.11.017     Document Type: Review

References (235)

1. Abel E.L. Marihuana and memory: acquisition or retrieval?. Science 1971, 173:1038-1040.
2. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol 2004, 7(Suppl. 1):S1-S5.
3. Abi-Dargham A., Gil R., Krystal J., Baldwin R.M., Seibyl J.P., Bowers M., et al. Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 1998, 155:761-767.
4. Achim A.M., Lepage M. Episodic memory-related activation in schizophrenia: meta-analysis. Br J Psychiatry 2005, 187:500-509.
5. Aleman A., Kahn R.S. Strange feelings: do amygdala abnormalities dysregulate the emotional brain in schizophrenia?. Prog Neurobiol 2005, 77:283-298.
6. Aleman A., Hijman R., de Haan E.H., Kahn R.S. Memory impairment in schizophrenia: a meta-analysis. Am J Psychiatry 1999, 156:1358-1366.
7. Allen P., Larøi F., McGuire P.K., Aleman A. The hallucinating brain: a review of structural and functional neuroimaging studies of hallucinations. Neurosci Biobehav Rev 2008, 32:175-191.
8. Altamura M., Elvevag B., Blasi G., Bertolino A., Callicott J.H., Weinberger D.R., et al. Dissociating the effects of Sternberg working memory demands in prefrontal cortex. Psychiatry Res 2007, 154:103-114.
9. Andrews J., Wang L., Csernansky J.G., Gado M.H., Barch D.M. Abnormalities of thalamic activation and cognition in schizophrenia. Am J Psychiatry 2006, 163:463-469.
10. Angrist B., Van Kammen D.P. CNS stimulants as tools in the study of schizophrenia. Trends Neurosci 1984, 7:388-390.
11. Arce E., Leland D.S., Miller D.A., Simmons A.N., Winternheimer K.C., Paulus M.P. Individuals with schizophrenia present hypo- and hyperactivation during implicit cueing in an inhibitory task. Neuroimage 2006, 32:704-713.
12. Arnold S.E. The medial temporal lobe in schizophrenia. J Neuropsychiatry Clin Neurosci 1997, 9:460-470. [Summer].
13. Arseneault L., Cannon M., Witton J., Murray R.M. Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 2004, 184:110-117.
14. Atakan Z., Bhattacharyya S., Allen P., Martin-Santos R., Crippa J.A., Borgwardt S.J., et al. Cannabis affects people differently: inter-subject variation in the psychotogenic effects of delta9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers. Psychol Med 2013, 43:1255-1267.
15. Bäckman L., Jones S., Berger A.K., Laukka E.J., Small B.J. Multiple cognitive deficits during the transition to Alzheimer's disease. J Intern Med 2004, 256:195-204.
16. Baddeley A. Working memory 1986, Claredon Press, Oxford.
17. Ballard M.E., Bedi G., de Wit H. Effects of delta-9-tetrahydrocannabinol on evaluation of emotional images. J Psychopharmacol 2012, 26:1289-1298.
18. Barch D.M., Dowd E.C. Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions. Schizophr Bull 2010, 36:919-934.
19. Barkus E., Morrison P.D., Vuletic D., Dickson J., Ell P.J., Pilowsky L.S., et al. Does intravenous delta9-tetrahydrocannabinol increase dopamine release? A SPET study. J Psychopharmacol 2011, 25:1462-1468.
20. Behere R.V., Venkatasubramanian G., Arasappa R., Reddy N., Gangadhar B.N. Effect of risperidone on emotion recognition deficits in antipsychotic-naive schizophrenia: a short-term follow-up study. Schizophr Res 2009, 113:72-76.
21. Bhattacharyya S., Fusar-Poli P., Borgwardt S., Martin-Santos R., Nosarti C., O'Carroll C., et al. Modulation of mediotemporal and ventrostriatal function in humans by delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry 2009, 66:442-451.
22. Bhattacharyya S., Atakan Z., Martin-Santos R., Crippa J.A., Kambeitz J., Prata D., et al. Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of delta-9-tetrahydrocannabinol on midbrain and striatal function. Mol Psychiatry 2012, 17(12):1152-1155.
23. Bhattacharyya S., Crippa J.A., Allen P., Martin-Santos R., Borgwardt S., Fusar-Poli P., et al. Induction of psychosis by δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch Gen Psychiatry 2012, 69:27-36.
24. Block R.I., Wittenborn J.R. Marijuana effects on semantic memory: verification of common and uncommon category members. Psychol Rep 1984, 55:503-512.
25. Blumenfeld R.S., Ranganath C. Prefrontal cortex and long-term memory encoding: an integrative review of findings from neuropsychology and neuroimaging. Neuroscientist 2007, 13:280-291.
26. Böcker K.B., Hunault C.C., Gerritsen J., Kruidenier M., Mensinga T.T., Kenemans J.L. Cannabinoid modulations of resting state EEG theta power and working memory are correlated in humans. J Cogn Neurosci 2010, 22:1906-1916.
27. Borgwardt S.J., Allen P., Bhattacharyya S., Fusar-Poli P., Crippa J.A., Seal M.L., et al. Neural basis of delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiatry 2008, 64:966-973.
28. Bossong M.G., Allen P. PET and SPECT findings in patients with hallucinations. PET and SPECT in psychiatry 2013, Springer Verlag, Heidelberg, [In press].
29. Bossong M.G., Niesink R.J. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Prog Neurobiol 2010, 92:370-385.
30. Bossong M.G., van Berckel B.N., Boellaard R., Zuurman L., Schuit R.C., Windhorst A.D., et al. Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009, 34:759-766.
31. Bossong M.G., Jager G., van Hell H.H., Zuurman L., Jansma J.M., Mehta M.A., et al. Effects of delta9-tetrahydrocannabinol administration on human encoding and recall memory function: a pharmacological FMRI study. J Cogn Neurosci 2012, 24:588-599.
32. Bossong M.G., Jansma J.M., van Hell H.H., Jager G., Oudman E., Saliasi E., et al. Effects of delta9-tetrahydrocannabinol on human working memory function. Biol Psychiatry 2012, 71:693-699.
33. Bossong M.G., Jansma J.M., van Hell H.H., Jager G., Kahn R.S., Ramsey N.F. Default mode network in the effects of {increment}9-tetrahydrocannabinol (THC) on human executive function. PLoS One 2013, 8:e70074.
34. Bossong M.G., van Hell H.H., Jager G., Kahn R.S., Ramsey N.F., Jansma J.M. The endocannabinoid system and emotional processing: a pharmacological fMRI study with {increment}9-tetrahydrocannabinol. Eur Neuropsychopharmacol 2013 Dec, 23(12):1687-1697.
35. Braver T.S., Cohen J.D., Nystrom L.E., Jonides J., Smith E.E., Noll D.C. A parametric study of prefrontal cortex involvement in human working memory. Neuroimage 1997, 5:49-62.
36. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., De Bartolomeis A., et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 1997, 94:2569-2574.
37. Broyd S.J., Demanuele C., Debener S., Helps S.K., James C.J., Sonuga-Barke E.J. Default-mode brain dysfunction in mental disorders: a systematic review. Neurosci Biobehav Rev 2009, 33:279-296.
38. Buckner R.L., Andrews-Hanna J.R., Schacter D.L. The brain's default network: anatomy, function, and relevance to disease. Ann N Y Acad Sci 2008, 1124:1-38.
39. Cabeza R., Nyberg L. Neural bases of learning and memory: functional neuroimaging evidence. Curr Opin Neurol 2000, 13:415-421.
40. Callicott J.H., Bertolino A., Mattay V.S., Langheim F.J., Duyn J., Coppola R., et al. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb Cortex 2000, 10:1078-1092.
41. Callicott J.H., Mattay V.S., Verchinski B.A., Marenco S., Egan M.F., Weinberger D.R. Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down. Am J Psychiatry 2003, 160:2209-2215.
42. Caspi A., Moffitt T.E., Cannon M., McClay J., Murray R., Harrington H., et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005, 57:1117-1127.
43. Casswell S. Cannabis intoxication: effects of monetary incentive on performance, a controlled investigation of behavioural tolerance in moderate users of cannabis. Percept Mot Skills 1975, 41:423-434.
44. Ceccarini J., De Hert M., Van Winkel R., Peuskens J., Bormans G., Kranaster L., et al. Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia. Neuroimage 2013, 79:304-312.
45. Chait L.D., Perry J.L. Acute and residual effects of alcohol and marijuana, alone and in combination, on mood and performance. Psychopharmacology 1994, 115:340-349.
46. Chen J.P., Paredes W., Li J., Smith D., Lowinson J., Gardner E.L. Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology (Berl) 1990, 102:156-162.
47. Copolov D.L., Seal M.L., Maruff P., Ulusoy R., Wong M.T., Tochon-Danguy H.J., et al. Cortical activation associated with the experience of auditory hallucinations and perception of human speech in schizophrenia: a PET correlation study. Psychiatry Res 2003, 122:139-152.
48. Corbetta M., Shulman G.L. Control of goal-directed and stimulus-driven attention in the brain. Nat Rev Neurosci 2002, 3:201-215.
49. Corbetta M., Patel G., Shulman G.L. The reorienting system of the human brain: from environment to theory of mind. Neuron 2008, 58:306-324.
50. Cornblatt B.A., Keilp J.G. Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr Bull 1994, 20:31-46.
51. Cornblatt B.A., Risch N.J., Faris G., Friedman D., Erlenmeyer-Kimling L. The continuous performance test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families. Psychiatry Res 1988, 26:223-238.
52. Creese I., Burt D.R., Snyder S.H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976, 192:481-483.
53. Crippa J.A., Zuardi A.W., Martin-Santos R., Bhattacharyya S., Atakan Z., McGuire P., et al. Cannabis and anxiety: a critical review of the evidence. Hum Psychopharmacol 2009, 24:515-523.
54. Curran H.V., Brignell C., Fletcher S., Middleton P., Henry J. Cognitive and subjective dose-response effects of acute oral delta-9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology 2002, 164:61-70.
55. Curtis C.E., D'Esposito M. Persistent activity in the prefrontal cortex during working memory. Trends Cogn Sci 2003, 7:415-423.
56. D'Souza D.C., Perry E., MacDougall L., Ammerman Y., Cooper T., Wu Y.T., et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004, 29:1558-1572.
57. Dalton V.S., Long L.E., Weickert C.S., Zavitsanou K. Paranoid schizophrenia is characterized by increased CB(1) receptor binding in the dorsolateral prefrontal cortex. Neuropsychopharmacology 2011, 36:1620-1630.
58. Darley C.F., Tinklenberg J.R., Roth W.T., Hollister L.E., Atkinson R.C. Influence of marijuana on storage and retrieval processes in memory. Mem Cognit 1973, 1:196-200.
59. Darley C.F., Tinklenberg J.R., Roth W.T., Vernon S., Kopell B.S. Marijuana effects on long-term memory assessment and retrieval. Psychopharmacology 1977, 52:239-241.
60. 3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001, 103:9-15.
61. Der-Avakian A., Markou A. The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci 2012, 35:68-77.
62. D'Esposito M., Detre J.A., Alsop D.C., Shin R.K., Atlas S., Grossman M. The neural basis of the central executive system of working memory. Nature 1995, 378:279-281.
63. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
64. Dornbush R.L. Marijuana and memory: effects of smoking on storage. Trans N Y Acad Sci 1974, 36:94-100.
65. Drevets W.C., Gautier C., Price J.C., Kupfer D.J., Kinahan P.E., Grace A.A., et al. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 2001, 49:81-96.
66. Drummond S.P., Bischoff-Grethe A., Dinges D.F., Ayalon L., Mednick S.C., Meloy M.J. The neural basis of the psychomotor vigilance task. Sleep 2005, 28:1059-1068.
67. D'Souza D.C., Abi-Saab W.M., Madonick S., Forselius-Bielen K., Doersch A., Braley G., et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 2005, 57:594-608.
68. D'Souza D.C., Ranganathan M., Braley G., Gueorguieva R., Zimolo Z., Cooper T., et al. Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 2008, 33:2505-2516.
69. D'Souza D.C., Braley G., Blaise R., Vendetti M., Oliver S., Pittman B., et al. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of delta-9-tetrahydrocannabinol in humans. Psychopharmacology (Berl) 2008, 198:587-603.
70. Edwards J., Jackson H.J., Pattison P.E. Emotion recognition via facial expression and affective prosody in schizophrenia: a methodological review. Clin Psychol Rev 2002, 22:789-832.
71. Elvevag B., Goldberg T.E. Cognitive impairment in schizophrenia is the core of the disorder. Crit Rev Neurobiol 2000, 14:1-21.
72. Esslinger C., Englisch S., Inta D., Rausch F., Schirmbeck F., Mier D., et al. Ventral striatal activation during attribution of stimulus saliency and reward anticipation is correlated in unmedicated first episode schizophrenia patients. Schizophr Res 2012, 140:114-121.
73. Fakra E., Khalfa S., Da F.D., Besnier N., Delaveau P., Azorin J.M., et al. Effect of risperidone versus haloperidol on emotional responding in schizophrenic patients. Psychopharmacology (Berl) 2008, 200:261-272.
74. Fassbender C., Zhang H., Buzy W.M., Cortes C.R., Mizuiri D., Beckett L., et al. A lack of default network suppression is linked to increased distractibility in ADHD. Brain Res 2009, 1273:114-128.
75. Fehr C., Yakushev I., Hohmann N., Buchholz H.G., Landvogt C., Deckers H., et al. Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. Am J Psychiatry 2008, 165:507-514.
76. Fioravanti M., Carlone O., Vitale B., Cinti M.E., Clare L. A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia. Neuropsychol Rev 2005, 15:73-95.
77. Ford J.M., Gray M., Whitfield S.L., Turken A.U., Glover G., Faustman W.O., et al. Acquiring and inhibiting prepotent responses in schizophrenia: event-related brain potentials and functional magnetic resonance imaging. Arch Gen Psychiatry 2004, 61:119-129.
78. Foti D.J., Kotov R., Guey L.T., Bromet E.J. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry 2010, 167:987-993.
79. Frith C.D. Consciousness, information processing and schizophrenia. Br J Psychiatry 1979, 134:225-235.
80. Fusar-Poli P., Meyer-Lindenberg A. Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies. Schizophr Bull 2013, 39:33-42.
81. Fusar-Poli P., Placentino A., Carletti F., Landi P., Allen P., Surguladze S., et al. Functional atlas of emotional faces processing: a voxel-based meta-analysis of 105 functional magnetic resonance imaging studies. J Psychiatry Neurosci 2009, 34:418-432.
82. Fusar-Poli P., Crippa J.A., Bhattacharyya S., Borgwardt S.J., Allen P., Martin-Santos R., et al. Distinct effects of delta9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry 2009, 66:95-105.
83. Fusar-Poli P., Allen P., Bhattacharyya S., Crippa J.A., Mechelli A., Borgwardt S., et al. Modulation of effective connectivity during emotional processing by delta 9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol 2010, 13:421-432.
84. Garrity A.G., Pearlson G.D., McKiernan K., Lloyd D., Kiehl K.A., Calhoun V.D. Aberrant "default mode" functional connectivity in schizophrenia. Am J Psychiatry 2007, 164:450-457.
85. Gilboa A., Winocur G., Grady C.L., Hevenor S.J., Moscovitch M. Remembering our past: functional neuroanatomy of recollection of recent and very remote personal events. Cereb Cortex 2004, 14:1214-1225.
86. Giuffrida A., Leweke F.M., Gerth C.W., Schreiber D., Koethe D., Faulhaber J., et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 2004, 29:2108-2114.
87. Glass M., Dragunow M., Faull R.L. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997, 77:299-318.
88. Gold J.M. Cognitive deficits as treatment targets in schizophrenia. Schizophr Res 2004, 72:21-28.
89. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry 1996, 153:321-330.
90. Gur R.E., McGrath C., Chan R.M., Schroeder L., Turner T., Turetsky B.I., et al. An fMRI study of facial emotion processing in patients with schizophrenia. Am J Psychiatry 2002, 159:1992-1999.
91. Gur R.E., Turetsky B.I., Loughead J., Snyder W., Kohler C., Elliott M., et al. Visual attention circuitry in schizophrenia investigated with oddball event-related functional magnetic resonance imaging. Am J Psychiatry 2007, 164:442-449.
92. Hahn B., Ross T.J., Yang Y., Kim I., Huestis M.A., Stein E.A. Nicotine enhances visuospatial attention by deactivating areas of the resting brain default network. J Neurosci 2007, 27:3477-3489.
93. Hall W., Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009, 374:1383-1391.
94. Hall J., Whalley H.C., McKirdy J.W., Romaniuk L., McGonigle D., McIntosh A.M., et al. Overactivation of fear systems to neutral faces in schizophrenia. Biol Psychiatry 2008, 64:70-73.
95. Harmer C.J., Mackay C.E., Reid C.B., Cowen P.J., Goodwin G.M. Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol Psychiatry 2006, 59:816-820.
96. Hart C.L., van Gorp W., Haney M., Foltin R.W., Fischman M.W. Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology 2001, 25:757-765.
97. Hart C.L., Ward A.S., Haney M., Comer S.D., Foltin R.W., Fischman M.W. Comparison of smoked marijuana and oral delta(9)-tetrahydrocannabinol in humans. Psychopharmacology 2002, 164:407-415.
98. Hart C.L., Ilan A.B., Gevins A., Gunderson E.W., Role K., Colley J., et al. Neurophysiological and cognitive effects of smoked marijuana in frequent users. Pharmacol Biochem Behav 2010, 96:333-341.
99. Hasenkamp W., James G.A., Boshoven W., Duncan E. Altered engagement of attention and default networks during target detection in schizophrenia. Schizophr Res 2011, 125:169-173.
100. Heifets B.D., Castillo P.E. Endocannabinoid signaling and long-term synaptic plasticity. Annu Rev Physiol 2009, 71:283-306.
101. Henquet C., Rosa A., Krabbendam L., Papiol S., Fananas L., Drukker M., et al. An experimental study of catechol-o-methyltransferase Val(158)Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 2006, 31:2748-2757.
102. Henson R.N., Rugg M.D., Shallice T., Josephs O., Dolan R.J. Recollection and familiarity in recognition memory: an event-related functional magnetic resonance imaging study. J Neurosci 1999, 19:3962-3972.
103. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., De Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991, 11:563-583.
104. Hill M.N., Hillard C.J., Bambico F.R., Patel S., Gorzalka B.B., Gobbi G. The therapeutic potential of the endocannabinoid system for the development of a novel class of antidepressants. Trends Pharmacol Sci 2009, 30:484-493.
105. Holt D.J., Kunkel L., Weiss A.P., Goff D.C., Wright C.I., Shin L.M., et al. Increased medial temporal lobe activation during the passive viewing of emotional and neutral facial expressions in schizophrenia. Schizophr Res 2006, 82:153-162.
106. Hong L.E., Schroeder M., Ross T.J., Buchholz B., Salmeron B.J., Wonodi I., et al. Nicotine enhances but does not normalize visual sustained attention and the associated brain network in schizophrenia. Schizophr Bull 2011, 37:416-425.
107. Howes O.D., Egerton A., Allan V., McGuire P., Stokes P., Kapur S. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des 2009, 15:2550-2559.
108. Howes O.D., Kambeitz J., Kim E., Stahl D., Slifstein M., Abi-Dargham A., et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 2012, 69:776-786.
109. Hunault C.C., Mensinga T.T., Bocker K.B., Schipper C.M., Kruidenier M., Leenders M.E., et al. Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69mg delta-9-tetrahydrocannabinol (THC). Psychopharmacology (Berl) 2009, 204:85-94.
110. Iannetti G.D., Wise R.G. BOLD functional MRI in disease and pharmacological studies: room for improvement?. Magn Reson Imaging 2007, 25:978-988.
111. Ilan A.B., Smith M.E., Gevins A. Effects of marijuana on neurophysiological signals of working and episodic memory. Psychopharmacology (Berl) 2004, 176:214-222.
112. Ilan A.B., Gevins A., Coleman M., ElSohly M.A., De Wit H. Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. Behav Pharmacol 2005, 16:487-496.
113. Jansma J.M., Ramsey N.F., van der Wee N.J., Kahn R.S. Working memory capacity in schizophrenia: a parametric fMRI study. Schizophr Res 2004, 68:159-171.
114. Jansma J.M., Ramsey N.F., de Zwart J.A., van Gelderen P., Duyn J.H. fMRI study of effort and information processing in a working memory task. Hum Brain Mapp 2007, 28:431-440.
115. Jansma J.M., van Hell H.H., Vanderschuren L.J., Bossong M.G., Jager G., Kahn R.S., et al. THC reduces the anticipatory nucleus accumbens response to reward in subjects with a nicotine addiction. Transl Psychiatry 2013, 3:e234.
116. Jenko K.J., Hirvonen J., Henter I.D., Anderson K.B., Zoghbi S.S., Hyde T.M., et al. Binding of a tritiated inverse agonist to cannabinoid CB1 receptors is increased in patients with schizophrenia. Schizophr Res 2012, 141:185-188.
117. Jensen J., Willeit M., Zipursky R.B., Savina I., Smith A.J., Menon M., et al. The formation of abnormal associations in schizophrenia: neural and behavioral evidence. Neuropsychopharmacology 2008, 33:473-479.
118. Johnson M.R., Morris N.A., Astur R.S., Calhoun V.D., Mathalon D.H., Kiehl K.A., et al. A functional magnetic resonance imaging study of working memory abnormalities in schizophrenia. Biol Psychiatry 2006, 60:11-21.
119. Juckel G., Schlagenhauf F., Koslowski M., Wüstenberg T., Villringer A., Knutson B., et al. Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage 2006, 29:409-416.
120. Kaladjian A., Jeanningros R., Azorin J.M., Grimault S., Anton J.L., Mazzola-Pomietto P. Blunted activation in right ventrolateral prefrontal cortex during motor response inhibition in schizophrenia. Schizophr Res 2007, 97:184-193.
121. Kano M., Ohno-Shosaku T., Hashimotodani Y., Uchigashima M., Watanabe M. Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 2009, 89:309-380.
122. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 2003, 160:13-23.
123. Karniol I.G., Shirakawa I., Kasinski N., Pfeferman A., Carlini E.A. Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man. Eur J Pharmacol 1974, 28:172-177.
124. Katona I., Freund T.F. Multiple functions of endocannabinoid signaling in the brain. Annu Rev Neurosci 2012, 35:529-558.
125. Kee K.S., Kern R.S., Marshall B.D., Green M.F. Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings. Schizophr Res 1998, 31:159-165.
126. Kiehl K.A., Stevens M.C., Celone K., Kurtz M., Krystal J.H. Abnormal hemodynamics in schizophrenia during an auditory oddball task. Biol Psychiatry 2005, 57:1029-1040.
127. Klein T.A., Endrass T., Kathmann N., Neumann J., von Cramon D.Y., Ullsperger M. Neural correlates of error awareness. Neuroimage 2007, 34:1774-1781.
128. Klumpers L.E., Cole D.M., Khalili-Mahani N., Soeter R.P., te Beek E.T., Rombouts S.A.R.B., et al. Manipulating brain connectivity with delta(9)-tetrahydrocannabinol: a pharmacological resting state FMRI study. Neuroimage 2012, 63:1701-1711.
129. Knutson B., Adams C.M., Fong G.W., Hommer D. Anticipation of increasing monetary reward selectively recruits nucleus accumbens. J Neurosci 2001, 21:RC159.
130. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci U S A 1996, 93:9235-9240.
131. Laruelle M., Iyer R.N., Al-Tikriti M.S., Zea-Ponce Y., Malison R., Zoghbi S.S., et al. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 1997, 25:1-14.
132. Laruelle M., Abi-Dargham A., Gil R., Kegeles L., Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry 1999, 46:56-72.
133. Lepage M., Pelletier M., Achim A., Montoya A., Menear M., Lal S. Parietal cortex and episodic memory retrieval in schizophrenia. Psychiatry Res 2010, 182:191-199.
134. Leppanen J.M. Emotional information processing in mood disorders: a review of behavioral and neuroimaging findings. Curr Opin Psychiatry 2006, 19:34-39.
135. Leweke F.M., Koethe D. Cannabis and psychiatric disorders: it is not only addiction. Addict Biol 2008, 13:264-275.
136. Leweke F.M., Giuffrida A., Wurster U., Emrich H.M., Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999, 10:1665-1669.
137. Leweke F.M., Giuffrida A., Koethe D., Schreiber D., Nolden B.M., Kranaster L., et al. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophr Res 2007, 94:29-36.
138. Leweke F.M., Piomelli D., Pahlisch F., Muhl D., Gerth C.W., Hoyer C., et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2012, 2:e94.
139. Lieberman J.A., Kane J.M., Alvir J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 1987, 91:415-433.
140. Liem-Moolenaar M., te Beek E.T., de Kam M.L., Franson K.L., Kahn R.S., Hijman R., et al. Central nervous system effects of haloperidol on THC in healthy male volunteers. J Psychopharmacol 2010, 24:1697-1708.
141. Linszen D.H., Dingemans P.M., Lenior M.E. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994, 51:273-279.
142. Logan G.D., Cowan W.B., Davis K.A. On the ability to inhibit simple and choice reaction time responses: a model and a method. J Exp Psychol Hum Percept Perform 1984, 10:276-291.
143. Lundstrom B.N., Petersson K.M., Andersson J., Johansson M., Fransson P., Ingvar M. Isolating the retrieval of imagined pictures during episodic memory: activation of the left precuneus and left prefrontal cortex. Neuroimage 2003, 20:1934-1943.
144. Lupica C.R., Riegel A.C., Hoffman A.F. Marijuana and cannabinoid regulation of brain reward circuits. Br J Pharmacol 2004, 143:227-234.
145. Lustig C., Snyder A.Z., Bhakta M., O'Brien K.C., McAvoy M., Raichle M.E., et al. Functional deactivations: change with age and dementia of the Alzheimer type. Proc Natl Acad Sci U S A 2003, 100:14504-14509.
146. Malone D.T., Taylor D.A. Modulation by fluoxetine of striatal dopamine release following delta9-tetrahydrocannabinol: a microdialysis study in conscious rats. Br J Pharmacol 1999, 128:21-26.
147. Mandal M.K., Pandey R., Prasad A.B. Facial expressions of emotions and schizophrenia: a review. Schizophr Bull 1998, 24:399-412.
148. Manoach D.S. Prefrontal cortex dysfunction during working memory performance in schizophrenia: reconciling discrepant findings. Schizophr Res 2003, 60:285-298.
149. Manoach D.S., Schlaug G., Siewert B., Darby D.G., Bly B.M., Benfield A., et al. Prefrontal cortex fMRI signal changes are correlated with working memory load. Neuroreport 1997, 8:545-549.
150. Manoach D.S., Press D.Z., Thangaraj V., Searl M.M., Goff D.C., Halpern E., et al. Schizophrenic subjects activate dorsolateral prefrontal cortex during a working memory task, as measured by fMRI. Biol Psychiatry 1999, 45:1128-1137.
151. Manoach D.S., Gollub R.L., Benson E.S., Searl M.M., Goff D.C., Halpern E., et al. Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance. Biol Psychiatry 2000, 48:99-109.
152. Marazziti D., Consoli G., Picchetti M., Carlini M., Faravelli L. Cognitive impairment in major depression. Eur J Pharmacol 2010, 626:83-86.
153. Martinez D., Slifstein M., Broft A., Mawlawi O., Hwang D.R., Huang Y., et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 2003, 23:285-300.
154. Martinez D., Narendran R., Foltin R.W., Slifstein M., Hwang D.R., Broft A., et al. Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. Am J Psychiatry 2007, 164:622-629.
155. Mason M.F., Norton M.I., Van Horn J.D., Wegner D.M., Grafton S.T., Macrae C.N. Wandering minds: the default network and stimulus-independent thought. Science 2007, 315:393-395.
156. Mato S., Chevaleyre V., Robbe D., Pazos A., Castillo P.E., Manzoni O.J. A single in-vivo exposure to delta 9THC blocks endocannabinoid-mediated synaptic plasticity. Nat Neurosci 2004, 7:585-586.
157. McDonald J., Schleifer L., Richards J.B., de Wit H. Effects of THC on behavioral measures of impulsivity in humans. Neuropsychopharmacology 2003, 28:1356-1365.
158. McGorry P.D., Nelson B., Amminger G.P., Bechdolf A., Francey S.M., Berger G., et al. Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J Clin Psychiatry 2009, 70:1206-1212.
159. McGrath J., Saha S., Chant D., Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008, 30:67-76.
160. McKiernan K.A., Kaufman J.N., Kucera-Thompson J., Binder J.R. A parametric manipulation of factors affecting task-induced deactivation in functional neuroimaging. J Cogn Neurosci 2003, 15:394-408.
161. Milev P., Ho B.C., Arndt S., Andreasen N.C. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005, 162:495-506.
162. Miller L.L., Cornett T.L. Marijuana: dose effects on pulse rate, subjective estimates of intoxication, free recall and recognition memory. Pharmacol Biochem Behav 1978, 9:573-577.
163. Miller L., Cornett T., Brightwell D., McFarland D., Drew W.G., Wikler A. Marijuana and memory impairment: the effect of retrieval cues on free recall. Pharmacol Biochem Behav 1976, 5:639-643.
164. Miller L.L., Cornett T.L., Brightwell D.R., McFarland D.J., Drew W.G., Wikler A. Marijuana: effects on storage and retrieval of prose material. Psychopharmacology 1977, 51:311-316.
165. Miller L.L., McFarland D., Cornett T.L., Brightwell D. Marijuana and memory impairment: effect on free recall and recognition memory. Pharmacol Biochem Behav 1977, 7:99-103.
166. Miller L.L., Cornett T.L., Wikler A. Marijuana: effects on pulse rate, subjective estimates of intoxication and multiple measures of memory. Life Sci 1979, 25:1325-1330.
167. Moore T.H., Zammit S., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M., et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007, 370:319-328.
168. Morrison P.D., Zois V., McKeown D.A., Lee T.D., Holt D.W., Powell J.F., et al. The acute effects of synthetic intravenous delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med 2009, 39:1607-1616.
169. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
170. Murphy S.E., Norbury R., O'Sullivan U., Cowen P.J., Harmer C.J. Effect of a single dose of citalopram on amygdala response to emotional faces. Br J Psychiatry 2009, 194:535-540.
171. Murray L.J., Ranganath C. The dorsolateral prefrontal cortex contributes to successful relational memory encoding. J Neurosci 2007, 27:5515-5522.
172. Ng Cheong Ton J.M., Gerhardt G.A., Friedemann M., Etgen A.M., Rose G.M., Sharpless N.S., et al. The effects of delta 9-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: an in vivo electrochemical and in vivo microdialysis study. Brain Res 1988, 451:59-68.
173. Nielsen M.Ø., Rostrup E., Wulff S., Bak N., Lublin H., Kapur S., et al. Alterations of the brain reward system in antipsychotic naïve schizophrenia patients. Biol Psychiatry 2012, 71:898-905.
174. Nielsen M.O., Rostrup E., Wulff S., Bak N., Broberg B.V., Lublin H., et al. Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia. Arch Gen Psychiatry 2012, 69:1195-1204.
175. Norman D.A., Shallice T. Attention and action: willed and automatic control of behavior. Consciousness and self-regulation 1986, 1-18. Plenum, New York. R.J. Davidson, G.E. Schwarts, D. Shapiro (Eds.).
176. Northoff G., Walter M., Schulte R.F., Beck J., Dydak U., Henning A., et al. GABA concentrations in the human anterior cingulate cortex predict negative BOLD responses in fMRI. Nat Neurosci 2007, 10:1515-1517.
177. Nuechterlein K.H., Dawson M.E. Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr Bull 1984, 10:160-203.
178. Peterson B.S., Potenza M.N., Wang Z., Zhu H., Martin A., Marsh R., et al. An FMRI study of the effects of psychostimulants on default-mode processing during Stroop task performance in youths with ADHD. Am J Psychiatry 2009, 166:1286-1294.
179. Phan K.L., Angstadt M., Golden J., Onyewuenyi I., Popovska A., de Wit H. Cannabinoid modulation of amygdala reactivity to social signals of threat in humans. J Neurosci 2008, 28:2313-2319.
180. Phillips M.L., Ladouceur C.D., Drevets W.C. A neural model of voluntary and automatic emotion regulation: implications for understanding the pathophysiology and neurodevelopment of bipolar disorder. Mol Psychiatry 2008, 13:829,833-829,857.
181. Pinkham A.E., Penn D.L., Perkins D.O., Lieberman J. Implications for the neural basis of social cognition for the study of schizophrenia. Am J Psychiatry 2003, 160:815-824.
182. Pomarol-Clotet E., Salvador R., Sarro S., Gomar J., Vila F., Martinez A., et al. Failure to deactivate in the prefrontal cortex in schizophrenia: dysfunction of the default mode network?. Psychol Med 2008, 38:1185-1193.
183. Potkin S.G., Turner J.A., Brown G.G., McCarthy G., Greve D.N., Glover G.H., et al. Working memory and DLPFC inefficiency in schizophrenia: the FBIRN study. Schizophr Bull 2009, 35:19-31.
184. Ragland J.D., Laird A.R., Ranganath C., Blumenfeld R.S., Gonzales S.M., Glahn D.C. Prefrontal activation deficits during episodic memory in schizophrenia. Am J Psychiatry 2009, 166:863-874.
185. Raichle M.E., MacLeod A.M., Snyder A.Z., Powers W.J., Gusnard D.A., Shulman G.L. A default mode of brain function. Proc Natl Acad Sci U S A 2001, 98:676-682.
186. Rais M., Cahn W., van Haren N., Schnack H., Caspers E., Hulshoff Pol H., et al. Excessive brain volume loss over time in cannabis-using first episode schizophrenia patients. Am J Psychiatry 2008, 165:490-496.
187. Ranganathan M., D'Souza D.C. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl) 2006, 188:425-444.
188. Ridderinkhof K.R., Ullsperger M., Crone E.A., Nieuwenhuis S. The role of the medial frontal cortex in cognitive control. Science 2004, 306:443-447.
189. Robbins T.W., Ersche K.D., Everitt B.J. Drug addiction and the memory systems of the brain. Ann N Y Acad Sci 2008, 1141:1-21.
190. Rubia K., Russell T., Bullmore E.T., Soni W., Brammer M.J., Simmons A., et al. An fMRI study of reduced left prefrontal activation in schizophrenia during normal inhibitory function. Schizophr Res 2001, 52:47-55.
191. Salgado-Pineda P., Junque C., Vendrell P., Baeza I., Bargallo N., Falcon C., et al. Decreased cerebral activation during CPT performance: structural and functional deficits in schizophrenic patients. Neuroimage 2004, 21:840-847.
192. 11C]raclopride at dopamine receptors in human subjects. Am J Psychiatry 1997, 154:1209-1213.
193. Schlagenhauf F., Sterzer P., Schmack K., Ballmaier M., Rapp M., Wrase J., et al. Reward feedback alterations in unmedicated schizophrenia patients: relevance for delusions. Biol Psychiatry 2009, 65:1032-1039.
194. Schlicker E., Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 2001, 22:565-572.
195. Schneider F.C., Royer A., Grosselin A., Pellet J., Barral F.G., Laurent B., et al. Modulation of the default mode network is task-dependant in chronic schizophrenia patients. Schizophr Res 2011, 125:110-117.
196. Schoeler T., Bhattacharyya S. The effect of cannabis use on memory function: an update. Subst Abus Rehabil 2013, 4:11-27.
197. Schwindt G.C., Black S.E. Functional imaging studies of episodic memory in Alzheimer's disease: a quantitative meta-analysis. Neuroimage 2009, 45:181-190.
198. Seeman P., Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 1975, 188:1217-1219.
199. Segarra N., Bernardo M., Valdes M., Caldu X., Falcon C., Rami L., et al. Cerebellar deficits in schizophrenia are associated with executive dysfunction. Neuroreport 2008, 19:1513-1517.
200. Seidenberg M., Guidotti L., Nielson K.A., Woodard J.L., Durgerian S., Antuono P., et al. Semantic memory activation in individuals at risk for developing Alzheimer disease. Neurology 2009, 73:612-620.
201. Sergerie K., Chochol C., Armony J.L. The role of the amygdala in emotional processing: a quantitative meta-analysis of functional neuroimaging studies. Neurosci Biobehav Rev 2008, 32:811-830.
202. Sharma S., Moskowitz H. Effects of two levels of attention demand on vigilance performance under marihuana. Percept Mot Skills 1974, 38:967-970.
203. Shmuel A., Augath M., Oeltermann A., Logothetis N.K. Negative functional MRI response correlates with decreases in neuronal activity in monkey visual area V1. Nat Neurosci 2006, 9:569-577.
204. Simmonds D.J., Pekar J.J., Mostofsky S.H. Meta-analysis of go/no-go tasks demonstrating that fMRI activation associated with response inhibition is task-dependent. Neuropsychologia 2008, 46:224-232.
205. Solowij N. Cannabis and cognitive functioning 1998, Cambridge University Press, Cambridge.
206. Solowij N., Michie P.T. Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?. J Psychiatry Neurosci 2007, 32:30-52.
207. Stella N., Schweitzer P., Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 1997, 388:773-778.
208. Sternberg S. High-speed scanning in human memory. Science 1966, 153:652-654.
209. Stokes P.R., Mehta M.A., Curran H.V., Breen G., Grasby P.M. Can recreational doses of THC produce significant dopamine release in the human striatum?. Neuroimage 2009, 48:186-190.
210. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995, 215:89-97.
211. Surguladze S., Russell T., Kucharska-Pietura K., Travis M.J., Giampietro V., David A.S., et al. A reversal of the normal pattern of parahippocampal response to neutral and fearful faces is associated with reality distortion in schizophrenia. Biol Psychiatry 2006, 60:423-431.
212. Tanda G., Pontieri F.E., Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 1997, 276:2048-2050.
213. Tandon R., Keshavan M.S., Nasrallah H.A. Schizophrenia, "Just the Facts": what we know in 2008 part 1: overview. Schizophr Res 2008, 100:4-19.
214. Tandon R., Nasrallah H.A., Keshavan M.S. Schizophrenia, "just the facts" 4. Clinical features and conceptualization. Schizophr Res 2009, 110:1-23.
215. Vachon L., Sulkowski A., Rich E. Marihuana effects on learning, attention and time estimation. Psychopharmacologia 1974, 39:1-11.
216. van Hell H.H., Bossong M.G., Jager G., Kahn R.S., Ramsey N.F. Pharmacological Imaging of the Cannabinoid System (PhICS): towards understanding the role of the brain endocannabinoid system in human cognition. Int J Methods Psychiatr Res 2011, 20:10-27.
217. van Hell H.H., Jager G., Bossong M.G., Brouwer A., Jansma J.M., Zuurman L., et al. Involvement of the endocannabinoid system in reward processing in the human brain. Psychopharmacology (Berl) 2012, 219:981-990.
218. van Os J., Kapur S. Schizophrenia. Lancet 2009, 374:635-645.
219. Vink M., Ramsey N.F., Raemaekers M., Kahn R.S. Striatal dysfunction in schizophrenia and unaffected relatives. Biol Psychiatry 2006, 60:32-39.
220. Volz H., Gaser C., Hager F., Rzanny R., Ponisch J., Mentzel H., et al. Decreased frontal activation in schizophrenics during stimulation with the continuous performance test - a functional magnetic resonance imaging study. Eur Psychiatry 1999, 14:17-24.
221. Weil A.T., Zinberg N.E., Nelsen J.M. Clinical and psychological effects of marihuana in man. Science 1968, 162:1234-1242.
222. Weiss E.M., Siedentopf C., Golaszewski S., Mottaghy F.M., Hofer A., Kremser C., et al. Brain activation patterns during a selective attention test - a functional MRI study in healthy volunteers and unmedicated patients during an acute episode of schizophrenia. Psychiatry Res 2007, 154:31-40.
223. Weissman D.H., Roberts K.C., Visscher K.M., Woldorff M.G. The neural bases of momentary lapses in attention. Nat Neurosci 2006, 9:971-978.
224. Whitfield-Gabrieli S., Ford J.M. Default mode network activity and connectivity in psychopathology. Annu Rev Clin Psychol 2012, 8:49-76.
225. Whitfield-Gabrieli S., Thermenos H.W., Milanovic S., Tsuang M.T., Faraone S.V., McCarley R.W., et al. Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proc Natl Acad Sci U S A 2009, 106:1279-1284.
226. Williams L.M., Loughland C.M., Green M.J., Harris A.W., Gordon E. Emotion perception in schizophrenia: an eye movement study comparing the effectiveness of risperidone vs. haloperidol. Psychiatry Res 2003, 120:13-27.
227. Wilson R.I., Nicoll R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001, 410:588-592.
228. Wilson W.H., Ellinwood E.H., Mathew R.J., Johnson K. Effects of marijuana on performance of a computerized cognitive-neuromotor test battery. Psychiatry Res 1994, 51:115-125.
229. Winton-Brown T.T., Allen P., Bhattacharrya S., Borgwardt S.J., Fusar-Poli P., Crippa J.A., et al. Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an fMRI study. Neuropsychopharmacology 2011, 36:1340-1348.
230. 11C]OMAR. Neuroimage 2010, 52:1505-1513.
231. Woodard J.L., Seidenberg M., Nielson K.A., Antuono P., Guidotti L., Durgerian S., et al. Semantic memory activation in amnestic mild cognitive impairment. Brain 2009, 132:2068-2078.
232. Woodruff P.W., Wright I.C., Bullmore E.T., Brammer M., Howard R.J., Williams S.C., et al. Auditory hallucinations and the temporal cortical response to speech in schizophrenia: a functional magnetic resonance imaging study. Am J Psychiatry 1997, 154:1676-1682.
233. Zanettini C., Panlilio L.V., Alicki M., Goldberg S.R., Haller J., Yasar S. Effects of endocannabinoid system modulation on cognitive and emotional behavior. Front Behav Neurosci 2011, 5:57.
234. Zuardi A.W., Shirakawa I., Finkelfarb E., Karniol I.G. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) 1982, 76:245-250.
235. Zuurman L., Ippel A.E., Moin E., van Gerven J.M. Biomarkers for the effects of cannabis and THC in healthy volunteers. Br J Clin Pharmacol 2009, 67:5-21.